Quality of life (QoL) outcomes with futibatinib treatment in FOENIX-CCA2-A phase II study in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions/rearrangements

被引：0

作者：

Valle, J. W. ^{[1
]}

Hollebecque, A. ^{[2
]}

Furuse, J. ^{[3
]}

Goyal, L. ^{[4
]}

Meric-Bernstam, F. ^{[5
]}

Morlock, R. ^{[6
]}

He, Y. ^{[7
]}

Benhadji, K. ^{[8
]}

Bridgewater, J. ^{[9
]}

机构：

[1] Univ Manchester, Div Canc Sci, Christie NHS Fdn Trust, Manchester, Lancs, England

[2] Gustave Roussy, DITEP Drug Dev Dept, Villejuif, France

[3] Kyorin Univ, Dept Med Oncol, Sch Med, Tokyo, Japan

[4] Massachusetts Gen Hosp, Dept Med Hematol Oncol, Boston, MA 02114 USA

[5] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeut, Houston, TX 77030 USA

[6] YourCareChoice, Sci Collaborator, Ann Arbor, AL USA

[7] Taiho Oncol, Biostat, Princeton, NJ USA

[8] Taiho Oncol Inc, Clin Dev Dept, Princeton, NJ USA

[9] UCL, Dept Med Oncol, Canc Inst, London, England

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.036

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

58P

引用

页码：S263 / S264

页数：2

共 38 条

[1] Efficacy, safety, and quality of life (QoL) with futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements: FOENIX-CCA2
Furuse, J.
Goyal, L.
Meric-Bernstam, F.
Hollebecque, A.
Valle, J. W.
Morizane, C.
Karasic, T. B.
Abrams, T. A.
Kelley, R. K.
Cassier, P. A.
Klumpen, H-J.
Uboha, N.
Mahipal, A.
Mitchell, E.
Ahn, E.
Chang, H-M.
Masuda, K.
He, Y.
Benhadji, K. A.
Bridgewater, J. A.
ANNALS OF ONCOLOGY, 2020, 31 : S1288 - S1289
[2] FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements.
Goyal, Lipika
Meric-Bernstam, Funda
Hollebecque, Antoine
Valle, Juan W.
Morizane, Chigusa
Karasic, Thomas Benjamin
Furuse, Junji
He, Yaohua
Soni, Nital
Benhadji, Karim A.
Bridgewater, John A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[3] Foenix-CCA2 quality of life data for Futibatinib-treated intrahepatic cholangiocarcinoma (ICCA) patients with FGFR2 fusions/rearrangements
Moehler, M.
Valle, J. W.
Hollebecque, A.
Furuse, J.
Goyal, L.
Meric-Bernstam, F.
Epstein, R.
Salimi, T.
Wacheck, V
Liu, M.
Benhadji, K. A.
Bridgewater, J. A.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 223 - 224
[4] Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/other rearrangements: Subgroup analyses of a phase II study (FOENIX-CCA2)
Bridgewater, J.
Meric-Bernstam, F.
Hollebecque, A.
Valle, J. W.
Morizane, C.
Karasic, T.
Abrams, T.
Furuse, J.
Kelley, R. K.
Cassier, P.
Klumpen, H-J.
Uboha, N.
Mahipal, A.
Mitchell, E.
Ahn, E. R.
Chang, H-M.
Masuda, K.
He, Y.
Benhadji, K.
Goyal, L.
ANNALS OF ONCOLOGY, 2020, 31 : S261 - S262
[5] FOENIX-CCA2 quality of life data for futibatinib-treated intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions/rearrangements.
Valle, Juan W.
Hollebecque, Antoine
Furuse, Junji
Goyal, Lipika
Meric-Bernstam, Funda
Epstein, Robert S.
Salimi, Tehseen
Wacheck, Volker
Liu, Mei
Benhadji, Karim A.
Bridgewater, John A.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[6] Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements.
Goyal, Lipika
Meric-Bernstam, Funda
Hollebecque, Antoine
Morizane, Chigusa
Valle, Juan W.
Karasic, Thomas Benjamin
Abrams, Thomas Adam
Kelley, Robin Kate
Cassier, Philippe Alexandre
Furuse, Junji
Klumpen, Heinz-Josef
Chang, Heung-Moon
Chen, Li-Tzong
Komatsu, Yoshito
Masuda, Kunihiro
Ahn, Daniel H.
Li, Kate
Benhadji, Karim A.
Wacheck, Volker
Bridgewater, John A.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[7] Primary results of phase 2 FOENIX-CCA2: the irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements
Moehler, M.
Goyal, L.
Meric-Bernstam, F.
Hollebecque, A.
Morizane, C.
Valle, J. W.
Karasic, T. B.
Abrams, T. A.
Kelley, R. K.
Cassier, P.
Furuse, J.
Klumpen, H. -J
Chang, H. -M
Chen, L. -T
Komatsu, Y.
Masuda, K.
Ahn, D.
He, Y.
Soni, N.
Benhadji, K. A.
Bridgewater, J. A.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 222 - 222
[8] Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements.
Goyal, Lipika
Meric-Bernstam, Funda
Hollebecque, Antoine
Morizane, Chigusa
Valle, Juan W.
Karasic, Thomas B.
Abrams, Thomas A.
Kelley, Robin Kate
Cassier, Philippe
Furuse, Junji
Klumpen, Heinz-Josef
Chang, Heung-Moon
Chen, Li-Tzong
Komatsu, Yoshito
Masuda, Kunihiro
Ahn, Daniel
He, Yaohua
Soni, Nital
Benhadji, Karim A.
Bridgewater, John A.
CANCER RESEARCH, 2021, 81 (13)
[9] PATIENT-REPORTED OUTCOMES IN FUTIBATINIB-TREATED INTRAHEPATIC CHOLANGIOCARCINOMA PATIENTS WITH FGFR2 FUSIONS/REARRANGEMENTS: RESULTS FROM THE FOENIX-CCA2 STUDY
Bridgewater, J. A.
Hollebecque, A.
Furuse, J.
Goyal, L.
Meric-Bernstam, F.
Epstein, R. S.
Morlock, R.
Salimi, T.
Wacheck, V
Liu, M.
Benhadji, K.
Valle, J. W.
VALUE IN HEALTH, 2022, 25 (01) : S218 - S219
[10] FOENIX-101: A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements.
Goyal, Lipika
Bahleda, Rastilav
Furuse, Junji
Valle, Juan W.
Moehler, Markus Hermann
Oh, Do-Youn
Chang, Heung-Moon
Kelley, Robin Kate
Javle, Milind M.
Borad, Mitesh J.
Chen, Li-Tzong
Uboha, Nataliya Volodymyrivna
Klumpen, Heinz-Josef
O'Dwyer, Peter J.
Li, Daneng
Morizane, Chigusa
Huang, Jerry
Bridgewater, John A.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)

← 1 2 3 4 →